JP2007509110A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509110A5
JP2007509110A5 JP2006536092A JP2006536092A JP2007509110A5 JP 2007509110 A5 JP2007509110 A5 JP 2007509110A5 JP 2006536092 A JP2006536092 A JP 2006536092A JP 2006536092 A JP2006536092 A JP 2006536092A JP 2007509110 A5 JP2007509110 A5 JP 2007509110A5
Authority
JP
Japan
Prior art keywords
compound
formula
treatment
antagonist
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006536092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/052618 external-priority patent/WO2005039566A1/en
Publication of JP2007509110A publication Critical patent/JP2007509110A/ja
Publication of JP2007509110A5 publication Critical patent/JP2007509110A5/ja
Withdrawn legal-status Critical Current

Links

JP2006536092A 2003-10-24 2004-10-22 Ｃｂ１拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体とリパーゼ阻害剤とを含む組み合わせでの肥満症治療 Withdrawn JP2007509110A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03103961 2003-10-24
PCT/EP2004/052618 WO2005039566A1 (en) 2003-10-24 2004-10-22 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors

Publications (2)

Publication Number Publication Date
JP2007509110A JP2007509110A (ja) 2007-04-12
JP2007509110A5 true JP2007509110A5 (https=) 2007-09-06

Family

ID=34486362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536092A Withdrawn JP2007509110A (ja) 2003-10-24 2004-10-22 Ｃｂ１拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体とリパーゼ阻害剤とを含む組み合わせでの肥満症治療

Country Status (13)

Country Link
EP (1) EP1680106B1 (https=)
JP (1) JP2007509110A (https=)
CN (2) CN1921849A (https=)
AR (1) AR046132A1 (https=)
AT (1) ATE438394T1 (https=)
AU (1) AU2004283055A1 (https=)
BR (1) BRPI0415463A (https=)
CA (1) CA2543342A1 (https=)
DE (1) DE602004022445D1 (https=)
MX (1) MXPA06004390A (https=)
RU (1) RU2006117639A (https=)
TW (1) TW200528102A (https=)
WO (1) WO2005039566A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039996A (ko) * 2005-08-17 2008-05-07 솔베이 파머슈티컬스 게엠베하 칼륨 채널 억제 화합물의 사용 방법
CN102731418B (zh) * 2012-07-15 2015-03-11 浙江大学 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
CN113166068B (zh) * 2018-11-20 2024-08-16 上海科技大学 MmpL3抑制剂、组合物及其用途
CN117551046B (zh) * 2023-11-17 2025-10-28 广东药科大学附属第一医院 二氨基脲类hsl抑制剂、制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3335A1 (fr) * 2000-03-23 2001-09-27 Solvay Pharm Bv Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1
PL363751A1 (en) * 2001-03-22 2004-11-29 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
KR100903760B1 (ko) * 2001-09-21 2009-06-19 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체
IL157704A0 (en) * 2001-09-21 2004-03-28 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity
SE0104330D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
RU2344132C2 (ru) * 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
MXPA06002064A (es) * 2003-10-20 2006-05-19 Solvay Pharm Bv Derivados e 1h imidazol como moduladores del receptor cannabinoide.
MXPA06004434A (es) * 2003-10-24 2006-06-20 Solvay Pharm Gmbh Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos.

Similar Documents

Publication Publication Date Title
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2008510770A5 (https=)
EP1489077A4 (en) 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
JP2010501478A5 (https=)
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
JP2007519649A5 (https=)
SE0400284D0 (sv) Novel compounds
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
JP2002030084A5 (https=)
JP2010532387A5 (https=)
JP2006508953A5 (https=)
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
JP2016511262A5 (https=)
CN115315423A (zh) 取代芳基类化合物
JP2023552610A5 (https=)
JP2009541387A5 (https=)
IL313466A (en) Inhibiting creb binding protein (cbp)
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
WO2008137809A3 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
WO2006042954A8 (fr) Dérivés de 2-amido-4-phenylthiazole, leur préparation et leur application en thérapeutique